Skip to content

Serotonin: all studies

Page 261 of 407: studies 2,601 to 2,610 of 4,066, newest first. Back to the serotonin overview

Research

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part IV. Psilocybin

December 26, 2023 Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. preprint

Background: The primary psychoactive drug in magic mushrooms, psilocybin induces profound alterations in consciousness through its action at the 5-HT2A receptor. This comprehensive review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin.Areas of Uncertainty: Despite initial concerns that psilocybin could cause...

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview

December 26, 2023 Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. preprint

Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including conditions that have not benefited from prior interventions. The latter half of the twentieth century marked a revolution in the treatment of depression, anxiety, and psychosis, exemplified by the...

Molecular and Medical Aspects of Psychedelics

International Journal of Molecular Sciences December 23, 2023 Adam Wojtas, Krystyna Gołembiowska 16 citations

Psychedelics belong to the oldest psychoactive drugs. They arouse recent interest due to their therapeutic applications in the treatment of major depressive disorder, substance use disorder, end-of-life anxiety,= and anxiety symptoms, and obsessive–compulsive disorder. In this review, the current state of preclinical research on the mechanism of action, neurotoxicity, and behavioral impact of...

Application of psilocybin in mental health disorders

Theoretical and Natural Science December 20, 2023 Jingxuan Chen

Psilocybin is a naturally occurring psychoactive compound, which has been used for ages in traditional settings for religious and therapeutic use. Recent studies have renewed interest in psilocybin for its potential therapeutic benefits in treating depression and anxiety. The pharmacodynamics of psilocybin are complex, involving its rapid conversion to psilocin and its activity on various...

Limbic System Response to Psilocybin and Ketamine Administration in Rats: A Neurochemical and Behavioral Study

International Journal of Molecular Sciences December 20, 2023 Adam Wojtas, Agnieszka Bysiek, Marzena Maćkowiak et al. 16 citations

The pathophysiology of depression is related to the reduced volume of the hippocampus and amygdala and hypertrophy of the nucleus accumbens. The mechanism of these changes is not well understood; however, clinical studies have shown that the administration of the fast-acting antidepressant ketamine reversed the decrease in hippocampus and amygdala volume in depressed patients, and the magnitude...

DOI: 10.3390/ijms25010100 (opens in new tab) Psilocybin Limbic system Nucleus accumbens Amygdala +6

Psychedelic concentrations of nitrous oxide reduce functional differentiation in frontoparietal and somatomotor cortical networks.

Communications Biology December 19, 2023 Rui Dai, Zirui Huang, Tony E. Larkin et al. 7 citations

Despite the longstanding use of nitrous oxide and descriptions of its psychological effects more than a century ago, there is a paucity of neurobiological investigation of associated psychedelic experiences. We measure the brain's functional geometry (through analysis of cortical gradients) and temporal dynamics (through analysis of co-activation patterns) using human resting-state functional...

Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue

Life December 15, 2023 Gregory Ian Robinson, Dongping Li, Bo Wang et al. 19 citations

Inflammation plays a pivotal role in the development and progression of inflammatory bowel disease (IBD), by contributing to tissue damage and exacerbating the immune response. The investigation of serotonin receptor 2A (5-HT2A) ligands and transient receptor potential (TRP) channel ligands is of significant interest due to their potential to modulate key inflammatory pathways, mitigate the...

DOI: 10.3390/life13122345 (opens in new tab) Psilocybin Curcumin Inflammation Ketanserin +2

Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats

Translational Psychiatry December 14, 2023 Ivan Skorodumov, Rainer Spanagel, Jonathan R Reinwald et al. 25 citations

Abstract Alcohol Use Disorder (AUD) adversely affects the lives of millions of people, but still lacks effective treatment options. Recent advancements in psychedelic research suggest psilocybin to be potentially efficacious for AUD. However, major knowledge gaps remain regarding (1) psilocybin’s general mode of action and (2) AUD-specific alterations of responsivity to psilocybin treatment in...

First drug-checking study at an electronic festival and fentanyl detection in the central region of Mexico

Harm Reduction Journal December 10, 2023 Silvia L. Cruz, Miguel Bencomo-Cruz, María E. Medina-Mora et al. 10 citations

Abstract Background Perception of drug adulteration has increased in Mexico, but there is little research on adulterants and toxicity. The aim of this study was to identify drug composition in an electronic music outdoor festival nearby Mexico City. Methods The participants completed a questionnaire with demographic data, harm reduction strategies, drug-use patterns, history, and the drug they...

α-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant.

ACS Pharmacology & Translational Science December 8, 2023 Richard A Glennon, Mal Gorzata Dukat 3 citations

α-Ethyltryptamine (AET) is quite an interesting, but perhaps long-forgotten, centrally acting agent. Known for more than 75 years, AET was once clinically available as an antidepressant but was withdrawn shortly after its introduction. AET was subsequently controlled as a U.S. Schedule I substance due to its perceived abuse liability and/or toxicity but remains an agent of interest....